Androgen receptor blockers, 5-alpha-reductase inhibitors, and oral contraceptives can be considered, although their safe long-term use in patients at risk of or with a history of breast cancer or other gynecological malignancies remains unproven, even though none seem to carry a higher risk of gynecologic malignancy. Here, AR is linked to breast carcinoma.